Sugi Predict
/ Targets
/ SRI
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to SRI by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer |
PHASE3 | COMPLETED |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression |
PHASE3 | COMPLETED |
| Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors |
PHASE3 | COMPLETED |
| Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas |
PHASE1/PHASE2 | COMPLETED |
| Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer |
PHASE2 | COMPLETED |
| Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant |
PHASE1/PHASE2 | COMPLETED |
| Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy |
PHASE2 | RECRUITING |
| Sorafenib-RT Treatment for Liver Metastasis (SLIM) |
PHASE1/PHASE2 | COMPLETED |
| Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial |
PHASE2 | UNKNOWN |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine |
PHASE2 | RECRUITING |
| BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer |
PHASE2 | COMPLETED |
| Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation |
PHASE2 | COMPLETED |
| A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors |
PHASE2 | UNKNOWN |
| Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer |
PHASE1/PHASE2 | COMPLETED |
| Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer |
PHASE2 | COMPLETED |
| Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) |
PHASE1/PHASE2 | COMPLETED |
| Sunitinib for Advanced Thymus Cancer Following Earlier Treatment |
PHASE2 | COMPLETED |
| Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone |
PHASE2 | UNKNOWN |
| Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma |
PHASE2 | COMPLETED |
| Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery |
PHASE1/PHASE2 | COMPLETED |
| Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer |
PHASE1/PHASE2 | COMPLETED |
| Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes |
PHASE1 | COMPLETED |
| Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer |
PHASE1 | COMPLETED |
| Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Sertraline for the Treatment of Patients With Frontal Lobe Dementia (FLD) |
PHASE1 | COMPLETED |
| Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies |
PHASE1 | COMPLETED |
| Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer |
PHASE1 | COMPLETED |
| Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma |
PHASE1 | COMPLETED |
| A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a SRI binder may also engage these)